Ozempic and other popular injectable GLP-1 drugs aren’t just helping dieters shed pounds. They’re also leading to share price losses for top food stocks, Paul R. La Monica writes in this week’s edition of Barron’s. Conagra (CAG), which will report its fiscal fourth-quarter earnings on July 11, has been hurt by the rising popularity of Novo Nordisk’s (NVO) Ozempic and Wegovy as well as Eli Lilly’s (LLY) Mounjaro and Zepbound, the author notes. But Conagra Chief Operating Officer Tom McGough is confident that the company can adapt to a world where more consumers are focusing on eating smaller meals and enjoying healthier snacks. Inflation has also taken a big bite out of demand over the past two years but the pace of food price increases is finally starting to slow.